Child ; Cord Blood Stem Cell Transplantation ; adverse effects ; Cystitis ; therapy ; Hemorrhage ; therapy ; Humans ; Mesenchymal Stem Cell Transplantation ; adverse effects ; Postoperative Complications ; therapy

Lipases have catalytic active in both aqueous phase and the non-aqueous phase and have a wide range of application in various industrial areas.However,the high cost of lipase production has restricted its extensive use in industry.Solid state fermentation possesses many advantages,such as low requirement for devices,low energy consumption,low production cost,little pollution to environment and easily being popularized,which have made it an important means in microbial production of lipases.Owing to the rapidly increased energy cost and the people's awareness of environmental protection,the solid state fermentation technique,which was regarded as low-tech in the past,has regained attention and developed rapidly since the 1990s.The production of lipase by SSF technique was reviewed.Mainly contents describe its characteristics,including physical and chemical factors and bioreactors.

The molecular characterization of self-antigens expressed by human malignancies that are capable of elicitation of anti-tumor immune responses in patients has been an active field in hematology, oncology, and tumor immunology. More than 2000 tumor antigens have been identified. These significant progresses have led to the renaissance of tumor immunology and studies on novel anti-tumor immunotherapies in lymphomas, other hematologic malignancies and tumors. However, despite of the progress in the identification of these self-tumor antigens, current antigen-specific immunotherapies for tumors are far less satisfactory than that expected, which reflects the urgent need to improve our understanding on the basic principles underlying the selection of these self-tumor antigens. In order to develop more effective antigen-specific anti-tumor immunotherapies and to monitor the responses to these immunotherapies in patients with lymphomas and other malignancies, many additional questions need to be addressed. In this brief review, the progress in the identification of tumor antigens in lymphomas and other malignancies was outlined and the new principles of self-tumor antigens and their significance for future immunotherapies to these malignancies were summarized.
Antigens, Neoplasm ; classification ; immunology ; therapeutic use ; Autoantigens ; classification ; immunology ; Hematologic Neoplasms ; therapy ; Humans ; Immunotherapy ; methods ; trends ; Lymphoma ; immunology ; therapy ; Neoplasms ; immunology ; therapy

Cognition ; Cognition Disorders ; Humans ; Manganese ; Occupational Exposure

Child, Preschool ; Diarrhea, Infantile ; therapy ; Female ; Humans ; Infant ; Moxibustion

Objective:To evaluate the role of the left ventricular ejection fraction (LVEF) in coronary artery bypass grafting(CABG)patients. Methods: From 2004 to 2005,215 patients underwent CABG and there were 36 cases with LVEF0.40(normal LVEF group). Correlative data of the two groups were compared and analyzed statistically. Results: Compared with the normal EF group, the EuroSCORE of the low EF group was much higher (mean 6.4?1.7) and many more patients of the low EF group had concomitant moderate to severe mitral valve insufficiency and aneurysm that needed simultaneous surgical operation(55.6%).Two patients died in hospital(5.5%)in the low EF group whereas five patients in the normal EF group(2.8%, P

ObjectiveTo study the pharmacokinetics of iguratimod in rats. MethodsThe concentration ofiguratirnod in the samples was determined by HPLC method. The pharmacokineties parameters were calculated withDAS softwrare. ResultsThe mainpharmacokineties parameters of normal group(6mg/kg) were as follows:t1/2Ke:3.56h, tpeak: 4.00h, Cmax : 8.87μg/ml, AUC0.24 : 74.76μg· ml-1·h-1. The main pharmacokineties parameters of threemodel groups(3,6,12mg/kg) were as follows: t1/2Ke: 4.54,3.20,3.17h, tpcak:3.83,3.83,4.67h,Cmax:3.84, 8.31,12.69μg/ml, AUC0.24 :40.21,76. 72,117.06μg·ml-1·h-1. Except Cmax and AUC, no significant differenceswere found between the three model groups. And the differences between normal group and model group were notsignificant. ConclusionThe pharmacokinetics of rats ks fit to one-compartment model.

Objective To evaluate the effect of dexmedetomidine on acute kidney injury after cardiac valve replacement with cardiopulmonary bypass (CPB).Methods One hundred patients of both sexes with rheumatic heart disease,aged 32-64 yr,weighing 46-75 kg,of American Society of Anesthesiologists physical status Ⅱ or Ⅲ (New York Heart Association class Ⅱ or Ⅲ),scheduled for elective cardiac valve replacement with CPB,were divided into 2 groups (n =50 each) using a random number table:control group (group C) and dexmedetomidine group (group D).Dexmedetomidine was intravenously infused in a loading dose of 1 μg/kg over 10 min before induction of anesthesia followed by an infusion of 0.4 μg · kg-1 · h-1 until 24 h after operation in group D,while the equal volume of normal saline was given in group C.The urine output per hour during the postoperative 48 h period was recorded.At 6,12,24,36 and 48 h after operation,blood samples were collected from the median cubital vein for determination of serum creatinine levels.The development and severity of acute kidney injury were determined according to the urine output and serum creatinine level.Results Compared with group C,the incidence and severity of acute kidney injury were significantly decreased in the postoperative 48 h period in group D (P＜0.05).Conclusion Dexmedetomidine infused in a loading dose of 1 μg/kg over 10 min before induction of anesthesia followed by an infusion of 0.4 μg · kg-1 · h-1 until 24 h after operation can reduce the development and severity of acute kidney injury after cardiac valve replacement with CPB in patients.

Objective To explore the relation ship between expression of survivin gene in leukemia cells and its clinical effects, and to study the mechanism of survivin resist-apoptosis function in leukemia.Methods Survivin expression was detected by Western blots analysis and expressions of Fas and Caspase were examined by immunohistochemistry in 18 leukemia patients.Results Thirteen cases in peripheral blood mononuclear cell survivin positive expression was detected in 18 leukemia patients(72.2%), but no survivin expression in 10 normal persons. There were significant difference of survivin expression in ALL/ANLL patients groups and different WBC groups(P